Bosh sahifaBMY • NYSE
add
Bristol Myers Squibb
60,18 $
Seans yopilganidan keyin:(0,30%)-0,18
60,00 $
Yopilgan:6-mar, 19:36:30 (GMT-5) · USD · NYSE · Ogohlantirish
Yopilish kursi
59,82 $
Kunlik diapazon
59,03 $ - 60,70 $
Yillik diapazon
39,35 $ - 61,10 $
Bozor kapitalizatsiyasi
122,06 mlrd USD
Oʻrtacha hajm
12,03 mln
Narx/foyda
-
Dividend daromadliligi
4,12%
Asosiy maydon
NYSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 12,34 mlrd | 7,54% |
Joriy xarajat | 6,33 mlrd | -7,11% |
Sof foyda | 72,00 mln | -95,91% |
Sof foyda marjasi | 0,58 | -96,22% |
Har bir ulushga tushum | 1,67 | -1,76% |
EBITDA | 4,65 mlrd | 5,57% |
Amaldagi soliq stavkasi | 56,57% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 10,86 mlrd | -11,57% |
Jami aktivlari | 92,60 mlrd | -2,69% |
Jami passivlari | 76,22 mlrd | 16,05% |
Umumiy kapital | 16,39 mlrd | — |
Tarqatilgan aksiyalar | 2,03 mlrd | — |
Narxi/balansdagi bahosi | 7,43 | — |
Aktivlardan daromad | 7,51% | — |
Kapitaldan daromad | 10,26% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 72,00 mln | -95,91% |
Operatsiyalardan naqd pul | 4,44 mlrd | 4,40% |
Sarmoyadan naqd pul | -196,00 mln | 85,44% |
Moliyadan naqd pul | -1,64 mlrd | -269,80% |
Naqd pulning sof oʻzgarishi | 2,45 mlrd | -37,89% |
Boʻsh pul | 4,24 mlrd | -12,74% |
Haqida
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts, Braine-l'Alleud, Belgium, Tokyo, Japan, Hyderabad; Bangalore, India and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut. Wikipedia
Tashkil etilgan
1887
Sayt
Xodimlar soni
34 100
